Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

The approval also allows certain patients to receive Enhertu earlier in their treatment course. Previously, it was typically used after both endocrine therapy and chemotherapy. Under the new ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan ... Kadcyla was once tipped to become the go-to treatment for HER2-positive breast cancer when first line HER2 drugs like Herceptin ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

For a doctor to prescribe Enhertu, the cancer must involve HER2 in some way. Each of these cancers also has other specific criteria for treatment with Enhertu, including prior treatments received.

the FDA approved Enhertu in stomach cancer following prior treatment with a trastuzumab (Herceptin)-based regimen. That second-line nod was based on results from the phase 2 Destiny-Gastric01 ...

metastatic breast cancer who received multiple lines of prior treatment, and was headlined at last year's ASCO congress. In the 557-patient study, Enhertu reduced the risk of disease progression ...

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.

(Reuters) - The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are ...